FDA Clears New Cancer Therapy, Companion Diagnostic and Low‑Dose MRI Agent — What Clinicians Need to Know

The US Food and Drug Administration has recently approved multiple oncology products — spanning a targeted therapy, a companion diagnostic and a low‑dose MRI contrast agent — expanding treatment and diagnostic options for patients with specific tumour profiles.

Truqap (capivasertib): First Targeted Approval for PTEN‑Deficient mAPMN/S Prostate Cancer

AstraZeneca’s AKT inhibitor Truqap (capivasertib) received FDA approval for use in combination with Zytiga (abiraterone) and androgen deprivation therapy (ADT) for adults with PTEN‑deficient, metastatic androgen pathway modulation‑naïve or sensitive (mAPMN/S) prostate cancer — the first targeted therapy authorised specifically for this PTEN‑deficient population.

The decision was based on the Phase III CAPItello‑281 trial (NCT04493853), in which the triplet regimen reduced the risk of radiographic disease progression or death by 19% versus Zytiga plus ADT and extended median radiographic progression‑free survival (rPFS) by 7.5 months.

PTEN loss is associated with more aggressive disease and poorer prognosis; investigators estimate roughly one in four patients with metastatic hormone‑sensitive prostate cancer (previously mHSPC) harbour PTEN‑deficient tumours.

Daniel George, CAPItello‑281 investigator and director of genitourinary oncology at Duke Cancer Institute, called encouraging and sustaining remission in these patients a "high priority," describing Truqap’s approval as a "significant clinical advance" with potential to change disease course.

AstraZeneca has also submitted Truqap for review in Europe. The drug is already approved in certain patients with hormone receptor‑positive, HER2‑negative advanced breast cancer who harbour PIK3CA, AKT1 or PTEN alterations and have progressed on prior endocrine therapy.

VENTANA PTEN (SP218) RxDx: FDA’s First CDx For PTEN Deficiency In Prostate Cancer

Roche’s VENTANA PTEN (SP218) RxDx assay received FDA approval as a pre‑treatment companion diagnostic to identify PTEN‑deficient prostate adenocarcinomas and determine eligibility for Truqap. The assay was used as the enrolment test in CAPItello‑281, underscoring the expanding role of CDx tests to personalise oncology care based on tumour genetics.

Ambelvist (gadoquatrane): Low‑Dose Gadolinium MRI Agent Approved For All Ages

Bayer’s macrocyclic gadolinium‑based contrast agent Ambelvist (gadoquatrane) was approved for use in adults, paediatric patients and term neonates to help detect abnormal or damaged tissue with atypical vascularity. The approval was supported by the global Phase III QUANTI programme, which found improved lesion visualisation at a reduced gadolinium dose and a favourable safety profile across age groups.

Jill Carbone, Bayer’s VP and Head of Radiology, North America Product & Pipeline, said the agent's low Gd dose will "support healthcare providers" in following guidance to use the lowest effective gadolinium dose for imaging.

Ambelvist carries a boxed warning addressing risks associated with intrathecal administration and the potential for nephrogenic systemic fibrosis (NSF) in patients with severe renal impairment; clinicians should follow contraindications and dosing guidance carefully.

Keytruda Plus Welireg: New Adjuvant Option For High‑Risk ccRCC

MSD secured FDA approval to use Keytruda (pembrolizumab) in combination with the HIF‑2α inhibitor Welireg (belzutifan) as adjuvant therapy for patients with intermediate‑high or high‑risk clear cell renal cell carcinoma (ccRCC) following nephrectomy. This expands post‑surgical treatment options for patients at elevated risk of recurrence.

Notably, Keytruda’s first market exclusivity protections are expected to expire in 2028, a context that may affect future market dynamics.

What This Means For Clinicians And Patients

• Truqap plus Zytiga and ADT offers a new targeted option for PTEN‑deficient mAPMN/S patients, a population with historically limited choices.
• VENTANA PTEN (SP218) RxDx enables precise pre‑treatment identification of eligible patients for Truqap therapy.
• Ambelvist provides a lower‑dose gadolinium option for improved lesion visualisation across age groups, but requires attention to renal safety and administration route warnings.
• Keytruda + Welireg adds an adjuvant strategy for high‑risk ccRCC post‑surgery.

Disclosure: This article summarises recent FDA actions for informational purposes and does not substitute for official prescribing information or clinical judgement. Clinicians should consult product labels, trial publications and regulatory notices for full prescribing, safety and eligibility details.